lung cancer

News
Roche’s Alecensa fast-tracked in China

Roche’s Alecensa fast-tracked in China

China's national regulator has granted a rapid approval for Roche’s lung cancer treatment Alecensa just months after European and American approvals, following a revamp of the country's not

News
NICE recommends Pfizer’s Xalkori in rare lung cancer

NICE recommends Pfizer’s Xalkori in rare lung cancer

NICE has issued a Final Appraisal Determination that recommends the use of Pfizer’s Xalkori (crizotinib) in England under the Cancer Drugs Fund (CDF) for patients with ROS1-positive advanced non-small cell lung cancer (NSCLC).